City

Los Angeles (1)

Condition

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8 (1)

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

Human Papillomavirus Positive (1)

Oropharyngeal Squamous Cell Carcinoma (1)

Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

p16 Positive Neoplastic Cells Present (1)

Overall Status

Active, not recruiting (1)

Phase

phase 1/phase 2 (1)

Sponsor

Jonsson Comprehensive Cancer Center (1)

Collaborator

AstraZeneca (1)

Intervention

durvalumab (1)

modified radical neck dissection (1)

quality-of-life assessment (1)

questionnaire administration (1)

stereotactic body radiation therapy (1)

transoral robotic surgery (1)

tremelimumab (1)

Study Documents

Intervention Type

biological (1)

other (1)

procedure (1)

radiation (1)

Funder Type

Other (1)

Study Type

Interventional (1)

p16 positive neoplastic cells present

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical

Active, not recruiting

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8
+8 more

Durvalumab
+6 more

Los Angeles, California

UCLA / Jonsson Comprehensive Cancer Center

Dec 7, 2021